A study investigating how a cellular enzyme affects blood glucose levels in mice provides clues to pathways that may be involved in processes including the regulation of longevity and the proliferation of tumor cells. In their report in the January 22 issue of Cell, a Massachusetts General Hospital (MGH)-based team of researchers describes the mechanism by which absence of the enzyme SIRT6 induces a fatal drop in blood sugar in mice by triggering a switch between two critical cellular processes. "We found that SIRT6 functions as a master regulator of glucose levels by maintaining the normal processes by which cells convert glucose into energy, " says Raul Mostoslavsky, MD, PhD, of the MGH Cancer Center, who led the study.
Thousands of children and teenagers with diabetes in the UK are left disenfranchised and at risk of developing serious health complications, because they feel healthcare professionals and schools don't always listen to their needs and help them control their diabetes. This is the finding of a report by Diabetes UK. We are now calling for improved provision of and access to educational and psychological support for children and young people with diabetes. The report's findings Last year 61 per cent of children and young people with diabetes aged up to 17 years said that they rarely felt able to talk about their needs or only able to talk about them "some of the time" when trying to discuss their diabetes care goals with their healthcare team.
Diabetes UK's Annual Professional Conference (APC) is coming to the Arena and Convention Centre (ACC) in Liverpool from 3 to 5 March 2010. The APC is the only event of its kind in the UK that is exclusively for healthcare professionals and scientists working in the area of diabetes. One of the largest in the UK It is one of the largest healthcare conferences in the UK with around 3, 000 attendees and provides people with the chance to: - explore a variety of different aspects of diabetes - share best practice - find out about the latest research - network with colleagues The theme for the APC 2010 is 'Diabetes: challenges in all ages', exploring the challenges posed by diabetes from children to older age.
New research that significantly improves our understanding of how insulin interacts with cells in the human body is published today. The study could have major implications for the development of treatments for Type I diabetes. By developing and analysing a range of super active insulins, scientists from the York Structural Biology Laboratory at the University of York have been able to identify common features that point to the likely molecular structure of human insulin when it is active in the body. The research also offers new insight into how insulin binds to insulin receptors on cells. The research was conducted with colleagues at the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, and is published in the journal Proceedings of the National Academy of Sciences.
Novo Nordisk announced that the US Food and Drug Administration (FDA) has granted marketing authorisation for Victoza® for the treatment of type 2 diabetes in adults. Victoza® is the brand name approved in the US and Europe for liraglutide, the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes. In the US, Victoza® is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes. This provides for Victoza® to be used in monotherapy, as second-line treatment and in combination with commonly prescribed oral medications for diabetes. "The US approval of Victoza®
A tiny new sensor could provide fresh, inexpensive diagnosis and treatment methods for people suffering from a variety of diseases. University of Florida engineers have designed and tested versions of the sensor for applications ranging from monitoring diabetics' glucose levels via their breath to detecting possible indicators of breast cancer in saliva. They say early results are promising - particularly considering that the sensor can be mass produced inexpensively with technology already widely used for making chips in cell phones and other devices. "This uses known manufacturing technology that is already out there, " said Fan Ren, a professor of chemical engineering and one of a team of engineers collaborating on the project.
The neuropeptide corticotropin-releasing factor (CRF) makes cameo appearances throughout the body, but its leading role is as the opening act in the stress response, jump-starting the process along the hypothalamus-pituitary-adrenal (HPA) axis. Researchers at the Salk Institute for Biological Studies have found that CRF also plays a part in the pancreas, where it increases insulin secretion and promotes the division of the insulin-producing beta cells. These findings, which will be published in this week's edition of the Proceedings of the National Academy of Sciences, may provide new insights into diabetes, particularly type 1, as well as suggest novel targets for drug intervention.
Phase 2 Trial Of LX4211 Demonstrates Significant And Rapid Improvements In Multiple Parameters In Type 2 Diabetic Patients
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, obtained positive results from a recently completed Phase 2 study of LX4211 in patients with type 2 diabetes mellitus. LX4211 is a once-per-day, orally-delivered, small molecule drug candidate that inhibits the sodium-dependent glucose transporter 2 (SGLT2), lowering the accumulation of glucose in the body and reducing caloric load. LX4211, dosed as a single agent, provided improvements in glycemic control, demonstrating statistically significant benefits in the primary and multiple secondary efficacy endpoints.
A new study has shown that metformin, a drug often used in the treatment of diabetes mellitus, is safe for use in treating patients who have both diabetes and advanced heart failure. The study was published in the Journal of Cardiac Failure by researchers at the David Geffen School of Medicine at UCLA and is now online here. "There may be over two million individuals with heart failure and type II diabetes mellitus in the U. S. alone, so this important finding will have fairly broad impact, " said Dr. Tamara Horwich, senior author of the study and an assistant professor of medicine in the division of cardiology at the David Geffen School of Medicine at UCLA.
Annals of Internal Medicine : Cultural Competency Training and Performance Reports to Improve Diabetes Care for Black Patients - In this study, researchers measure the effects cultural competency training and performance training for physicians has on the clinical outcomes for black patients with diabetes. By comparing the patient outcomes among blacks whose physicians received training to those who had not, the authors conclude that though "cultural competency training combined with individual clinician-level performance feedback on racial disparities â increased awareness of disparities, " such changes were "not accompanied by improvement in diabetes outcomes for black patients.